Rising GLP-1 Drug Costs Drive Health Insurer Spending Surge in 2025

Health insurance companies in the U.S. are experiencing significant increases in medical expenses, particularly driven by higher prescription drug costs in 2025. Many insurers report that spending on drugs in the first nine months of 2025 has already exceeded total drug expenditures for the entire year of 2024, with some noting over 20% growth in drug-related expenses. A primary contributor to this surge is the rising use of GLP-1 medications, injectable drugs known for promoting substantial weight loss. This increased utilization of GLP-1s is causing insurers and employers to reevaluate their coverage policies, with some considering dropping coverage for these drugs altogether. The trend highlights the ongoing challenges insurers face in forecasting drug expenditures and managing premium costs amid rapid changes in pharmaceutical utilization and market dynamics. This development is part of a broader pattern of health insurance cost pressures driven by medication spending and utilization growth, impacting insurer financial planning and potentially influencing benefit design and plan affordability for employers and consumers.